Comments to FDA: Remote Regulatory Assessments Draft Guidance Share page: Docket Number: FDA-2022-D-0810 CHPA appreciates the opportunity to provide comments on FDA Remote Regulatory Assessments Draft Guidance. Download Document Issues: OTC Medicines Dietary Supplements Consumer Medical Devices Related Posts Comments Comments Regarding Reauthorization of the Over-the-Counter Monograph Drug User Fee Program Oct 27, 2023 Timeline for an FDA Order to Determine a Drug is Not GRAS/E Oct 20, 2023 Press Releases and Statements CHPA SVP of Regulatory & Scientific Affairs Delivers Remarks at FDA OMUFA Public Meeting Sep 28, 2023